Ausgabe 1/2019
Inhalt (8 Artikel)
T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
Myo Htut
T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders
Jennifer Crombie, Philippe Armand
Stem Cell Transplantation (R Maziarz, Section Editor)
Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?
Bronwen E. Shaw
Stem Cell Transplantation (R Maziarz, Section Editor)
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Sarah A. Holstein, Vera J. Suman, Philip L. McCarthy
Stem Cell Transplantation (R Maziarz, Section Editor)
Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Shalin Kothari, Jens Hillengass, Philip L. McCarthy, Sarah A. Holstein
Stem Cell Transplantation (R Maziarz, Section Editor)
Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy
Stacie Ittershagen, Solveig Ericson, Lamis Eldjerou, Ali Shojaee, Eric Bleickardt, Manisha Patel, Tetiana Taran, Oezlem Anak, Charlene Hall, Mimi Leung, Deborah Roccoberton, Florence Salmon, Miriam Fuchs, Vadim Romanov, David Lebwohl
Chronic Myeloid Leukemias (M Mauro, Section Editor)
Treatment-Free Remission in CML: the US Perspective
Guru Subramanian Guru Murthy, Ehab Atallah
Correction
Correction to: Strategies for Predicting Response to Checkpoint Inhibitors
Roberta Zappasodi, Jedd D. Wolchok, Taha Merghoub